Bellevue Group AG
Q1 2025 13F-HR Holdings
Net value change ($000)
-732,255
(-14.1%)
New positions
10
Sold out positions
22
Turnover %
9.2%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2024
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| AKRO | 50,627 | NEW |
| ALNY | 26,163 | 14.4% |
| SYK | 23,681 | 12.6% |
| ABBV | 20,292 | 252.3% |
| BAX | 15,624 | NEW |
| ABT | 15,417 | 8.1% |
| MCK | 9,572 | 87.0% |
| BEAM | 9,144 | 24.3% |
| MASI | 7,635 | 191.1% |
| LH | 6,500 | 13000.0% |
Top Reduces (Value $000, Stocks/ETFs)
| Intra-Cellular Therapies, Inc. | -203,809 | -100.0% |
| NBIX | -47,138 | -19.0% |
| ARVN | -45,809 | -100.0% |
| IONS | -38,159 | -13.9% |
| RVMD | -37,208 | -19.4% |
| ISRG | -31,527 | -13.0% |
| TNDM | -28,184 | -100.0% |
| SRRK | -27,915 | -25.7% |
| BHVN | -27,164 | -35.6% |
| Sage Therapeutics, Inc. | -24,222 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|